Literature DB >> 17392596

The value of Tc-99m tetrofosmin in the imaging of pituitary adenomas.

N Kurtulmus1, C Turkmen, S Yarman, H Tokmak, A Mudun.   

Abstract

AIM: Magnetic resonance imaging (MRI) and computerized tomography (CT) are used in the diagnosis and follow-up of pituitary adenoma cases. Sometimes, these methods cannot display the post-operative residual tissue. It has been shown that some radionuclides were taken up by the pituitary adenomas. The aim of this study was to evaluate the uptake of the technetium-99m (Tc-99m) tetrofosmin (TF) in the pituitary adenoma and normal pituitary tissue and assess the ability of Tc-99m TF to predict tumor malignancy in pituitary gland.
METHODS: The patients with pituitary adenoma (7 invasive and 8 non-invasive) were compared with control group (no. 13). Single-photon emission computed tomography (SPECT) imaging of pituitary gland was performed in both groups. Tc-99m uptake indices were evaluated statistically with the use of Mann-Whitney U test.
RESULTS: The average tetrofosmin uptake index of pituitary adenoma is 2.44+/-1.54 for the patients and 1.69+/-0.71 for the control group. Any significant difference was not observed between the groups (p 0.3). The average index was calculated as 3.04+/-2.15 for invasive adenomas and 1.92+/-0.33 for the non-invasive group, and there was no significant difference between the two groups regarding uptake of the agent (p 0.53). Furthermore, it was determined that the invasive and non-invasive adenomas displayed an uptake of Tc-99m TF similar to normal pituitary tissue.
CONCLUSIONS: Since the pituitary adenoma and normal pituitary tissue gave similar results regarding Tc-99m TF uptake, it was concluded that this agent would not be useful in the diagnosis of pituitary adenoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17392596     DOI: 10.1007/BF03347404

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  24 in total

1.  In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.

Authors:  W W de Herder; A E Reijs; D J Kwekkeboom; L J Hofland; F R Nobels; H Y Oei; E P Krenning; S W Lamberts
Journal:  Clin Endocrinol (Oxf)       Date:  1996-12       Impact factor: 3.478

2.  Technetium-99m-tetrofosmin for parathyroid scintigraphy: a comparison with sestamibi.

Authors:  J G Fjeld; K Erichsen; P F Pfeffer; O P Clausen; K Rootwelt
Journal:  J Nucl Med       Date:  1997-06       Impact factor: 10.057

3.  Parathyroid hyperplasia, thymic carcinoid and pituitary adenoma detected with technetium-99m-MIBI in MEN type I.

Authors:  J E Perez-Monte; M L Brown; M R Clarke; C G Watson; S E Carty
Journal:  J Nucl Med       Date:  1997-11       Impact factor: 10.057

4.  A comparative study of technetium-99m sestamibi and technetium-99m tetrofosmin single-photon tomography in the detection of nasopharyngeal carcinoma.

Authors:  L Kostakoglu; U Uysal; E Ozyar; F B Demirkazik; M Hayran; L Atahan; C F Bekdik
Journal:  Eur J Nucl Med       Date:  1997-06

5.  Brain tumor imaging with 99mTc-tetrofosmin: comparison with 201Tl, 99mTc-MIBI, and 18F-fluorodeoxyglucose.

Authors:  J Y Choi; S E Kim; H J Shin; B T Kim; J H Kim
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

6.  Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.

Authors:  U Plöckinger; M Reichel; U Fett; W Saeger; H J Quabbe
Journal:  J Clin Endocrinol Metab       Date:  1994-11       Impact factor: 5.958

7.  Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors.

Authors:  G Oppizzi; R Cozzi; D Dallabonzana; P Orlandi; Z Benini; M Petroncini; R Attanasio; M Milella; G Banfi; M Possa
Journal:  J Endocrinol Invest       Date:  1998-09       Impact factor: 4.256

8.  Technetium-99m sestamibi brain single-photon emission tomography for detection of recurrent gliomas after radiation therapy.

Authors:  C Soler; P Beauchesne; K Maatougui; T Schmitt; F G Barral; D Michel; F Dubois; J Brunon
Journal:  Eur J Nucl Med       Date:  1998-12

9.  Uptake of technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 in tumor cell lines.

Authors:  A S Arbab; K Koizumi; K Toyama; T Araki
Journal:  J Nucl Med       Date:  1996-09       Impact factor: 10.057

10.  Technetium-99m pentavalent dimercaptosuccinic acid imaging in patients with pituitary adenomas.

Authors:  S Lastoria; A Colao; E Vergara; D Ferone; P Varrella; B Merola; G Lombardi; M Salvatore
Journal:  Eur J Endocrinol       Date:  1995-07       Impact factor: 6.664

View more
  1 in total

Review 1.  Metabolic In Vivo Visualization of Pituitary Adenomas: a Systematic Review of Imaging Modalities.

Authors:  Amy Yao; Priti Balchandani; Raj K Shrivastava
Journal:  World Neurosurg       Date:  2017-04-28       Impact factor: 2.104

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.